Pharma Focus Asia

Aratana Therapeutics Announces Study Results for AT-016

Saturday, December 16, 2017

Aratana Therapeutics, Inc. has received top-line pivotal field effectiveness study results for AT-016, an investigational adipose-derived allogeneic stem cell therapeutic candidate for the control of clinical signs associated with osteoarthritis.

On December 14, 2017, Aratana's license partner responsible for the development of AT-016 shared the results of a pivotal study, which did not achieve protocol-defined efficacy success criteria. As part of Aratana's exclusive commercial license for dogs with osteoarthritis in the United States, Aratana had funded the clinical study and other work. Aratana anticipates that after its license partner has further evaluated the study results, the parties will determine if the collaboration to bring the therapeutic to market will continue.

"Recently, the focus has been on the commercialization of our three FDA-approved pet therapeutics ENTYCE, NOCITA, and GALLIPRANT," explained Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "However, Aratana continues to invest in a pipeline of development-stage therapeutic candidates. While we are disappointed with this individual study result, we have had our successes and will continue to execute on our pet therapeutics business model."

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024